NCT05200429 Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF
| NCT ID | NCT05200429 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of British Columbia |
| Condition | Cystic Fibrosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2021-11-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2021-11-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational study intends to investigate health trends and data in cystic fibrosis patients all across Canada that are receiving modulator treatment so researchers can determine if CFTR treatments are effective over a long period of time and if so, which treatments work best for each individual. The study will collect clinical data from routine standard of care, patient reported outcomes via survey data and samples for a biobank.
Eligibility Criteria
Inclusion Criteria: * Prescribed a CFTR modulator therapy and planning to commence modulator therapy within 30 days OR planning to switch modulator therapies within 30 days * Participates in the Canadian Cystic Fibrosis Registry (CCFR) * Informed consent by participant, or parent/legal guardian or assent Exclusion Criteria: * Known contraindications to CFTR modulator therapy
Contact & Investigator
Jonathan Rayment, MDCM
PRINCIPAL INVESTIGATOR
University of British Columbia
Frequently Asked Questions
Who can join the NCT05200429 clinical trial?
This trial is open to participants of all sexes, studying Cystic Fibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05200429 currently recruiting?
Yes, NCT05200429 is actively recruiting participants. Contact the research team at alam.lakhani@cw.bc.ca for enrollment information.
Where is the NCT05200429 trial being conducted?
This trial is being conducted at Vancouver, Canada, Vancouver, Canada.
Who is sponsoring the NCT05200429 clinical trial?
NCT05200429 is sponsored by University of British Columbia. The principal investigator is Jonathan Rayment, MDCM at University of British Columbia. The trial plans to enroll 500 participants.